The Experts below are selected from a list of 11778 Experts worldwide ranked by ideXlab platform
Werner Tjarks - One of the best experts on this subject based on the ideXlab platform.
-
Carboranyl thymidine analogues for Neutron Capture Therapy
Chemical communications (Cambridge England), 2007Co-Authors: Werner Tjarks, Sureshbabu Narayanasamy, Youngjoo Byun, Rohit Tiwari, Rolf F BarthAbstract:Neutron Capture Therapy (NCT) is a binary radio-chemotherapeutic modality for the treatment of cancer. A major focus of NCT-related research is the development of novel tumor-selective agents that serve as the chemical component in NCT. Thymidine analogues substituted with a boron-containing carborane cluster at the N3 position, designated 3CTAs (3-carboranyl thymidine analogues), constitute one class of these new improved NCT agents. Their chemical, structural and biological properties are discussed in this Feature Article.
-
Boronated thymidine analogues for boron Neutron Capture Therapy.
Nucleosides nucleotides & nucleic acids, 2006Co-Authors: B. T. S. Thirumamagal, Rolf F Barth, Jayaseharan Johnsamuel, Guirec Y. Cosquer, Youngjoo Byun, Junhua Yan, Sureshbabu Narayanasamy, Werner Tjarks, Ashraf S. Al-madhoun, Staffan ErikssonAbstract:Concise synthetic methods for synthesizing 3-carboranyl thymidine analogues (3CTAs) modified with cyclic and acyclic alcohols have been developed. The synthesis of these potential boron Neutron Capture Therapy (BNCT) agents and their preliminary biological evaluation is described.
-
Synthesis of para- and nido-carboranyl phenanthridinium compounds for Neutron Capture Therapy
Tetrahedron Letters, 1996Co-Authors: Werner Tjarks, Hadi Ghaneolhosseini, Cecilia L.a Henssen, Jonas Malmquist, Stefan SjöbergAbstract:Abstract The syntheses of two novel para -carboranyl and two novel nido -carboranyl phenanthridinium compounds as potential boron delivery agents for Neutron Capture Therapy are described
Yasushi Shibata - One of the best experts on this subject based on the ideXlab platform.
-
In Vivo and In Vitro Uptake Study of Boronated Porphyrins for Neutron Capture Therapy
Frontiers in Neutron Capture Therapy, 2001Co-Authors: Akira Matsumura, Yasushi Shibata, Tetsuya Yamamoto, Isao Sakata, Susumu Nakajima, Fumiyo Yoshida, Kei Nakai, Masafumi Okumura, Tadao NoseAbstract:To improve boron Neutron Capture Therapy (BNCT), a new tumor-seeking drug is required. Boronated porphyrins have been developed for boron carriers in boron Neutron Capture Therapy (BNCT) with some positive results.1, 2, 3, 4, 5 We have developed a boronated metalloporphyrin compound, STA-BX900, and previously reported its significance compared to borocaptate sodium (BSH).3 To improve the delivery of such compounds to the tumor, two other types of boron porphyrin compounds, whose side chains were slightly modified, have been evaluated. The in vivo and in vitro uptake study of these drugs will be presented.
-
Neutron Capture Therapy with a new boron-porphyrin compound in the rat 9L glioma model
Journal of experimental & clinical cancer research : CR, 1998Co-Authors: Yasushi Shibata, Akira Matsumura, Tetsuya Yamamoto, Tadao Nose, Isao Sakata, Keiichi Nakagawa, Y. Yoshii, S. Nakajima, Y. Hayakawa, K. OnoAbstract:Neutron Capture Therapy with a new boron-porphyrin compound was tested in a rat brain tumor model. Although the concentration of boron in the tumor was too low to elicit a therapeutic effect, prominent histopathologic changes, such as necrosis, congestion and bleeding were observed in the tumors of the rats which were administered the boron Neutron Capture Therapy.
-
Boron-, Gadolinium-Porphyrin Derivatives for Neutron Capture Therapy
Cancer Neutron Capture Therapy, 1996Co-Authors: Akira Matsumura, Yasushi Shibata, Kunio Nakagawa, Tetsuya Yamamoto, Takashi Yoshizawa, Yoshihiko Yoshii, Tadao Nose, Isao Sakata, Susumu Nakajima, Naoto MiwaAbstract:New porphyrin derivatives conjugated with boron(B) or gadolinium(Gd) were developed to use as compound for Neutron Capture Therapy in order to obtain tumor selective accumulation of B or Gd. In Neutron Capture Therapy, it is essential to know the B or Gd distribution in the tumor and in the normal brain. Using sodium borocaptate (BSH), detection of the boron concentration in the tumor and blood before the Therapy require operative sampling and additional analysis such as inductively coupled plasma (ICP) analysis (1) and still the intratumoral heterogeneity of B distribution can not be analyzed precisely. Our study was aimed to develop B or Gd compounds for Neutron Capture Therapy which could be visualized on MRI. This compound enables preoperative evaluation of the spatial distribution of B or Gd and its clearance from the tissue without operative samplings. Such porphyrin derivatives are thought to be useful in Neutron Capture Therapy.
-
The Measurement of Gadolinium Concentration in Rat Brain Tumor with NMR Analyzer for Neutron Capture Therapy
Cancer Neutron Capture Therapy, 1996Co-Authors: Yasushi Shibata, Akira Matsumura, Kunio Nakagawa, Tetsuya Yamamoto, Yoshihiko Yoshii, T. Nose, S. Sakata, Susumu NakajimaAbstract:Sufficient concentration of gadolinium or boron in brain tumor is key in performing effective Neutron Capture Therapy. As we know, the effect of Neutron Capture reaction is determined by the concentration of gadolinium or boron in tumor, the density of the Neutron flux and radiation time. And the ratios of gadolinium concentrations in the tumor to that in normal tissues and to that in blood are important keys for successful Neutron Capture Therapy. Gadolinium-DTPA is a commercially available and clinically safe agent for contrast enhancement in magnetic resonance imaging. The pharmacodynamics of gadolinium-DTPA in rat blood and brain tumor after intravenous infusion shows fast peak and fast wash out(1). In order to perform effective gadolinium Neutron Capture Therapy we must develop new gadolinium compounds which show significant and continuous uptake in brain tumor. We have reported continuous significant uptake of boron or gadolinium in rat brain tumor using porphyrin derivatives(2) or monoclonal antibody(3). These gadolinium porphyrin derivatives, named Gd-ATN-10, was developed for Neutron Capture Therapy. This molecule contains the porphyrin structure and manganese and gadolinium-DTPA(Fig.1). Gadolinium is a paramagnetic metal, which increases the intensity of T1 weighted magnetic resonance imaging and decreases the T1 relaxation time.
Stefan Sjöberg - One of the best experts on this subject based on the ideXlab platform.
-
The Synthesis of Functional Derivatives of the [1-CB9H10]- Anion for Boron Neutron Capture Therapy
ChemInform, 2004Co-Authors: Igor B. Sivaev, Stefan Sjöberg, Vladimir I. BregadzeAbstract:The Synthesis of Functional Derivatives of the [1-CB9H10]- Anion for Boron Neutron Capture Therapy
-
Cellular spheroids as a micrometastasis model in preclinical tests of boron Neutron Capture Therapy
2001Co-Authors: Joergen Carlsson, Stefan Sjöberg, E. Bohl, Katarina Edwards, Per Nilsson, Anna Sjöström, Lars GeddaAbstract:Cellular spheroids as a micrometastasis model in preclinical tests of boron Neutron Capture Therapy
-
Synthesis of a boronated naphthalimide for potential use in boron Neutron Capture Therapy (BNCT).
Acta chemica Scandinavica (Copenhagen Denmark : 1989), 1999Co-Authors: Hadi Ghaneolhosseini, Stefan SjöbergAbstract:Synthesis of a boronated naphthalimide for potential use in boron Neutron Capture Therapy (BNCT)
-
Synthesis of para- and nido-carboranyl phenanthridinium compounds for Neutron Capture Therapy
Tetrahedron Letters, 1996Co-Authors: Werner Tjarks, Hadi Ghaneolhosseini, Cecilia L.a Henssen, Jonas Malmquist, Stefan SjöbergAbstract:Abstract The syntheses of two novel para -carboranyl and two novel nido -carboranyl phenanthridinium compounds as potential boron delivery agents for Neutron Capture Therapy are described
Akira Matsumura - One of the best experts on this subject based on the ideXlab platform.
-
In Vivo and In Vitro Uptake Study of Boronated Porphyrins for Neutron Capture Therapy
Frontiers in Neutron Capture Therapy, 2001Co-Authors: Akira Matsumura, Yasushi Shibata, Tetsuya Yamamoto, Isao Sakata, Susumu Nakajima, Fumiyo Yoshida, Kei Nakai, Masafumi Okumura, Tadao NoseAbstract:To improve boron Neutron Capture Therapy (BNCT), a new tumor-seeking drug is required. Boronated porphyrins have been developed for boron carriers in boron Neutron Capture Therapy (BNCT) with some positive results.1, 2, 3, 4, 5 We have developed a boronated metalloporphyrin compound, STA-BX900, and previously reported its significance compared to borocaptate sodium (BSH).3 To improve the delivery of such compounds to the tumor, two other types of boron porphyrin compounds, whose side chains were slightly modified, have been evaluated. The in vivo and in vitro uptake study of these drugs will be presented.
-
Neutron Capture Therapy with a new boron-porphyrin compound in the rat 9L glioma model
Journal of experimental & clinical cancer research : CR, 1998Co-Authors: Yasushi Shibata, Akira Matsumura, Tetsuya Yamamoto, Tadao Nose, Isao Sakata, Keiichi Nakagawa, Y. Yoshii, S. Nakajima, Y. Hayakawa, K. OnoAbstract:Neutron Capture Therapy with a new boron-porphyrin compound was tested in a rat brain tumor model. Although the concentration of boron in the tumor was too low to elicit a therapeutic effect, prominent histopathologic changes, such as necrosis, congestion and bleeding were observed in the tumors of the rats which were administered the boron Neutron Capture Therapy.
-
Boron-, Gadolinium-Porphyrin Derivatives for Neutron Capture Therapy
Cancer Neutron Capture Therapy, 1996Co-Authors: Akira Matsumura, Yasushi Shibata, Kunio Nakagawa, Tetsuya Yamamoto, Takashi Yoshizawa, Yoshihiko Yoshii, Tadao Nose, Isao Sakata, Susumu Nakajima, Naoto MiwaAbstract:New porphyrin derivatives conjugated with boron(B) or gadolinium(Gd) were developed to use as compound for Neutron Capture Therapy in order to obtain tumor selective accumulation of B or Gd. In Neutron Capture Therapy, it is essential to know the B or Gd distribution in the tumor and in the normal brain. Using sodium borocaptate (BSH), detection of the boron concentration in the tumor and blood before the Therapy require operative sampling and additional analysis such as inductively coupled plasma (ICP) analysis (1) and still the intratumoral heterogeneity of B distribution can not be analyzed precisely. Our study was aimed to develop B or Gd compounds for Neutron Capture Therapy which could be visualized on MRI. This compound enables preoperative evaluation of the spatial distribution of B or Gd and its clearance from the tissue without operative samplings. Such porphyrin derivatives are thought to be useful in Neutron Capture Therapy.
-
The Measurement of Gadolinium Concentration in Rat Brain Tumor with NMR Analyzer for Neutron Capture Therapy
Cancer Neutron Capture Therapy, 1996Co-Authors: Yasushi Shibata, Akira Matsumura, Kunio Nakagawa, Tetsuya Yamamoto, Yoshihiko Yoshii, T. Nose, S. Sakata, Susumu NakajimaAbstract:Sufficient concentration of gadolinium or boron in brain tumor is key in performing effective Neutron Capture Therapy. As we know, the effect of Neutron Capture reaction is determined by the concentration of gadolinium or boron in tumor, the density of the Neutron flux and radiation time. And the ratios of gadolinium concentrations in the tumor to that in normal tissues and to that in blood are important keys for successful Neutron Capture Therapy. Gadolinium-DTPA is a commercially available and clinically safe agent for contrast enhancement in magnetic resonance imaging. The pharmacodynamics of gadolinium-DTPA in rat blood and brain tumor after intravenous infusion shows fast peak and fast wash out(1). In order to perform effective gadolinium Neutron Capture Therapy we must develop new gadolinium compounds which show significant and continuous uptake in brain tumor. We have reported continuous significant uptake of boron or gadolinium in rat brain tumor using porphyrin derivatives(2) or monoclonal antibody(3). These gadolinium porphyrin derivatives, named Gd-ATN-10, was developed for Neutron Capture Therapy. This molecule contains the porphyrin structure and manganese and gadolinium-DTPA(Fig.1). Gadolinium is a paramagnetic metal, which increases the intensity of T1 weighted magnetic resonance imaging and decreases the T1 relaxation time.
Tadao Nose - One of the best experts on this subject based on the ideXlab platform.
-
In Vivo and In Vitro Uptake Study of Boronated Porphyrins for Neutron Capture Therapy
Frontiers in Neutron Capture Therapy, 2001Co-Authors: Akira Matsumura, Yasushi Shibata, Tetsuya Yamamoto, Isao Sakata, Susumu Nakajima, Fumiyo Yoshida, Kei Nakai, Masafumi Okumura, Tadao NoseAbstract:To improve boron Neutron Capture Therapy (BNCT), a new tumor-seeking drug is required. Boronated porphyrins have been developed for boron carriers in boron Neutron Capture Therapy (BNCT) with some positive results.1, 2, 3, 4, 5 We have developed a boronated metalloporphyrin compound, STA-BX900, and previously reported its significance compared to borocaptate sodium (BSH).3 To improve the delivery of such compounds to the tumor, two other types of boron porphyrin compounds, whose side chains were slightly modified, have been evaluated. The in vivo and in vitro uptake study of these drugs will be presented.
-
Neutron Capture Therapy with a new boron-porphyrin compound in the rat 9L glioma model
Journal of experimental & clinical cancer research : CR, 1998Co-Authors: Yasushi Shibata, Akira Matsumura, Tetsuya Yamamoto, Tadao Nose, Isao Sakata, Keiichi Nakagawa, Y. Yoshii, S. Nakajima, Y. Hayakawa, K. OnoAbstract:Neutron Capture Therapy with a new boron-porphyrin compound was tested in a rat brain tumor model. Although the concentration of boron in the tumor was too low to elicit a therapeutic effect, prominent histopathologic changes, such as necrosis, congestion and bleeding were observed in the tumors of the rats which were administered the boron Neutron Capture Therapy.
-
Boron-, Gadolinium-Porphyrin Derivatives for Neutron Capture Therapy
Cancer Neutron Capture Therapy, 1996Co-Authors: Akira Matsumura, Yasushi Shibata, Kunio Nakagawa, Tetsuya Yamamoto, Takashi Yoshizawa, Yoshihiko Yoshii, Tadao Nose, Isao Sakata, Susumu Nakajima, Naoto MiwaAbstract:New porphyrin derivatives conjugated with boron(B) or gadolinium(Gd) were developed to use as compound for Neutron Capture Therapy in order to obtain tumor selective accumulation of B or Gd. In Neutron Capture Therapy, it is essential to know the B or Gd distribution in the tumor and in the normal brain. Using sodium borocaptate (BSH), detection of the boron concentration in the tumor and blood before the Therapy require operative sampling and additional analysis such as inductively coupled plasma (ICP) analysis (1) and still the intratumoral heterogeneity of B distribution can not be analyzed precisely. Our study was aimed to develop B or Gd compounds for Neutron Capture Therapy which could be visualized on MRI. This compound enables preoperative evaluation of the spatial distribution of B or Gd and its clearance from the tissue without operative samplings. Such porphyrin derivatives are thought to be useful in Neutron Capture Therapy.
